Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis

• Published in: Immunology 2014-03, Vol.141 (3), p.328-339
• Main Authors: Giunti, Debora, Parodi, Benedetta, Cordano, Christian, Uccelli, Antonio, Kerlero de Rosbo, Nicole
• Format: Article
• Language: English
• Subjects: Animals; anti‐inflammatory treatment; Brain - immunology; Brain - metabolism; Brain - pathology; Cell Communication; Genotype & phenotype; Humans; Immune system; Mesenchymal Stem Cell Transplantation; mesenchymal stem cells; microglia; Microglia - immunology; Microglia - metabolism; Microglia - pathology; Multiple sclerosis; Multiple Sclerosis - immunology; Multiple Sclerosis - metabolism; Multiple Sclerosis - pathology; Multiple Sclerosis - therapy; Neurodegenerative Diseases - immunology; Neurodegenerative Diseases - metabolism; Neurodegenerative Diseases - pathology; neuroinflammation; Neurons - immunology; Neurons - metabolism; Neurons - pathology; Phenotype; Review; Signal Transduction
• ISSN: 0019-2805; 1365-2567
• DOI: 10.1111/imm.12177

Summary Microglia cells, the resident innate immune cells in the brain, are highly active, extending and retracting highly motile processes through which they continuously survey their microenvironment for ‘danger signals’ and interact dynamically with surrounding cells. Upon sensing changes in their central nervous system microenvironment, microglia become activated, undergoing morphological and functional changes. Microglia activation is not an ‘all‐or‐none’ process, but rather a continuum depending on encountered stimuli, which is expressed through a spectrum of molecular and functional phenotypes ranging from so‐called ‘classically activated’, with a highly pro‐inflammatory profile, to ‘alternatively activated’ associated with a beneficial, less inflammatory, neuroprotective profile. Microglia activation has been demonstrated in most neurological diseases of diverse aetiology and has been implicated as a contributor to neurodegeneration. The possibility to promote microglia’s neuroprotective phenotype has therefore become a therapeutic goal. We have focused our discussion on the role of microglia in multiple sclerosis, a prototype of inflammatory, demyelinating, neurodegenerative disease, and on the effect of currently approved or on‐trial anti‐inflammatory therapeutic strategies that might mediate neuroprotection at least in part through their effect on microglia by modifying their behaviour via a switch of their functional phenotype from a detrimental to a protective one. In addition to pharmaceutical approaches, such as treatment with glatiramer acetate, interferon‐β, fingolimod or dimethyl fumarate, we address the alternative therapeutic approach of treatment with mesenchymal stem cells and their potential role in neuroprotection through their ‘calming’ effect on microglia.